Floatz logo

Eloxatin

Chemotherapy-induced Peripheral Neuropathy

Fox Chase Cancer CenterPhase 1/2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Chemotherapy-induced Peripheral Neuropathy cohort.

Asset / SponsorPhaseRating
LIDOCAINE
Hospital Ambroise Paré Paris
Phase 2BB
Huangqi-Guizhi-Wuwu Granules
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Phase 3B
Danggui-Sini Granules
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Phase 3B
Sodium Selenite Pentahydrate
Seoul National University Hospital
Phase 3B
Oxygen
Bernardino Clavo, MD, PhD
Phase 2/3B

View all 23 →

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →